Overview
Phylloceuticals develops plant-based bioprocessing technology (PhAAST™) using genetically modified tobacco (Nicotiana sp.) and Lemna sp. to produce therapeutic proteins, vaccine antigens, and antibodies faster and cheaper than traditional mammalian cell methods. The automated hydroponic and aquaculture systems enable rapid scaling, such as 50 million vaccine doses in 12 weeks, with no animal-derived products or human contact required. They focus on biosimilars, novel drugs, animal health, and clinical trial materials as a supplier to commercialization entities.
Frequently asked questions
- What bioprocessing technology does Phylloceuticals use?
- Phylloceuticals employs PhAAST™, an automated plant-based platform using hydroponically grown Nicotiana sp. and aquaculture-grown Lemna sp. to produce properly folded therapeutic proteins, vaccine antigens, and antibodies matching or exceeding human glycoforms.
- What products can Phylloceuticals manufacture?
- They produce biosimilars, novel drugs, animal health therapeutics, and clinical trial investigation materials, including kilograms of product in weeks via plant expression systems.
- What are the advantages of Phylloceuticals' plant-based approach?
- The technology offers faster production (e.g., 50 million vaccine doses in 12 weeks), lower costs (facilities under $120M vs. $1B+), reduced risk with no animal products or human contact, and no need for viral clearance studies.